Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Apr 28, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how a combination of two medications, dasatinib and quercetin, can help improve the effects of aging in older adults who are dealing with mental health conditions like treatment-resistant depression or schizophrenia. The study aims to understand if these drugs can help slow down the physical signs of aging in individuals aged 50 and older, especially those who have other health issues commonly associated with aging, such as high blood pressure or diabetes.

To participate in this trial, individuals must be at least 50 years old (or 60 for those with depression) and currently experiencing major depression that hasn’t improved with usual treatments, or have schizophrenia. Participants should be taking their standard medications for these conditions. Throughout the study, participants will receive the combination of dasatinib and quercetin and will be monitored by healthcare professionals for any effects. It's important to note that if someone has certain health conditions or is taking specific medications, they may not qualify for the trial. This study is currently recruiting participants, and anyone interested should discuss it with their doctor to see if it might be a good fit for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder.
• • 2. Age 50+ (60+ for depression).
• • 3. Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging).
• • 4. No history of dementia by patient report.
• • 5. Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression.
• Exclusion Criteria:
• • 1. Contraindications for dasatinib or quercetin
• • 2. Active SI such that participant could not be safely managed in an outpatient clinical trial.
• • 3. Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin).
• • 4. All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.